Comparison of two chemotherapy regimens, with or without cyclosporin A, in relapsed/refractory acute myeloid leukaemia: Results of the UK Medical Research Council AML-R trial.

被引：0
|
作者：
Yin, JAL
Wheatley, K
Rees, J
Burnett, A
机构：
[1] Manchester Royal Infirm, Manchester M13 9WL, Lancs, England
[2] CTSU Oxford, Oxford, England
[3] Addenbrookes Hosp, Cambridge, England
[4] Univ Wales Coll Med, Cardiff CF4 4XN, S Glam, Wales
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
946
引用
收藏
页码：231A / 231A
页数：1
相关论文
共 50 条
  • [21] Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial
    Mitchell, CD
    Richards, SM
    Kinsey, SE
    Lilleyman, J
    Vora, A
    Eden, TOB
    BRITISH JOURNAL OF HAEMATOLOGY, 2005, 129 (06) : 734 - 745
  • [22] Validation of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) Score for Hypomethylating Agents (HMAs) Use in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)
    Deveaux, Michelle
    Stahl, Maximilian
    Montesinos, Pau
    Itzykson, Raphael
    Ritchie, Ellen K.
    Sekeres, Mikkael A.
    Barnard, John
    Podoltsev, Nikolai A.
    Brunner, Andrew M.
    Komrokji, Rami S.
    Bhatt, Vijaya R.
    Al-Kali, Aref
    Cluzeau, Thomas
    Santini, Valeria
    Roboz, Gail J.
    Fenaux, Pierre
    Litzow, Mark R.
    Fathi, Amir T.
    Perreault, Sera
    Kim, Tae Kon
    Prebet, Thomas
    Vey, Norbert
    Verma, Vivek
    Germing, Ulrich
    Bergua, Juan
    Serrano, Josefina
    Gore, Steven D.
    Zeidan, Amer M.
    BLOOD, 2017, 130
  • [23] Early response to induction is predictive of survival in childhood Philadelphia chromosome positive acute lymphoblastic leukaemia: Results of the Medical Research Council ALL 97 trial.
    Roy, A
    Bradburn, M
    Moorman, AV
    Burrett, J
    Mitchell, C
    Kinsey, SE
    Vora, AJ
    Lilleyman, J
    Eden, O
    Hann, I
    Saha, V
    BLOOD, 2004, 104 (11) : 51A - 51A
  • [24] Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.
    De Botton, Stephane
    Yee, Karen W. L.
    Recher, Christian
    Wei, Andrew
    Montesinos, Pau
    Taussig, David
    Pigneux, Arnaud
    Braun, Thorsten
    Curti, Antonio
    Esteve, Jordi
    Grove, Carolyn
    Jonas, Brian Andrew
    Khwaja, Asim
    Legrand, Ollivier
    Peterlin, Pierre
    Polyanskaya, Olga
    Sweeney, Jennifer
    Mohamed, Hesham
    Cortes, Jorge E.
    Fenaux, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [25] Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial
    Burnett, AK
    Goldstone, AH
    Stevens, RMF
    Hann, IM
    Rees, JKH
    Gray, RG
    Wheatley, K
    LANCET, 1998, 351 (9104): : 700 - 708
  • [26] Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)
    Lu, Yu
    Liu, Ying
    Wen, Shupeng
    Kuang, Na
    Zhang, Xuejun
    Li, Jianqiang
    Wang, Fuxu
    JOURNAL OF TRANSLATIONAL MEDICINE, 2022, 20 (01)
  • [27] Naturally selected CD7 CAR-T therapy without genetic editing demonstrates significant antitumour efficacy against relapsed and refractory acute myeloid leukaemia (R/R-AML)
    Yu Lu
    Ying Liu
    Shupeng Wen
    Na Kuang
    Xuejun Zhang
    Jianqiang Li
    Fuxu Wang
    Journal of Translational Medicine, 20
  • [28] Incidence and Outcome of Osteonecrosis in Children and Young Adults with Acute Lymphoblastic Leukaemia Treated on a Dexamethasone Containing Protocol: Results of the Medical Research Council UK Trial ALL 2003
    Vora, Aiay
    Wade, Rachel
    Mitchell, Christopher
    Goulden, Nicholas
    Richards, Sue
    BLOOD, 2008, 112 (11) : 337 - 337
  • [29] A Randomized Phase II Trial of Three Novel Regimens for Relapsed/Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906
    Litzow, Mark R.
    Wang, Xin Victoria
    Carroll, Martin P.
    Karp, Judith E.
    Ketterling, Rhett
    Kaufmann, Scott H.
    Lazarus, Hillard M.
    Luger, Selina M.
    Paietta, Elisabeth M.
    Rowe, Jacob M.
    Altman, Jessica K.
    Pratz, Keith W.
    Broun, E. Randolph
    Tallman, Martin S.
    BLOOD, 2014, 124 (21)
  • [30] Dose escalation results of a phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in patients (Pts) with relapsed/refractory (r/r) acute myeloid leukemia (AML)
    Erba, Harry Paul
    Becker, Pamela S.
    Shami, Paul J.
    Grunwald, Michael Richard
    Flesher, Donna L.
    Zhang, Yilong
    Rasmussen, Erik
    Henary, Haby A.
    Wang, Eunice S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345